NCT02275156View on ClinicalTrials.gov

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 19, 2014

Primary Completion Date

December 19, 2014

Study Completion Date

December 19, 2014

Conditions
HyperlipidemiaMixed Dyslipidemia
Interventions
BIOLOGICAL

Evolocumab

Administered by subcutaneous injection

Trial Locations (1)

80230

Research Site, Denver

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY